Tumor‐infiltrating lymphocytes (TIL) in breast cancer have recently generated much interest as a prognostic factor 12 and predictive factor for neoadjuvant chemotherapy, especially in HER2‐positive subtype and TN cancers 13, 14. The gene discussed is ERBB2; the disease is breast carcinoma.